Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

被引:197
作者
Crettol, S
Déglon, JJ
Besson, J
Croquette-Krokkar, M
Gothuey, I
Hämmig, R
Monnat, M
Hüttemann, H
Baumann, P
Eap, CB [1 ]
机构
[1] Univ Lausanne, Hop Cery, Ctr Neurosci Psychiat, Dept Psychiat Adulte,Unite Biochim & Psychopharma, CH-1008 Lausanne, Switzerland
[2] Fdn Phenix, Geneva, Switzerland
[3] CHU Vaudois, Ctr St Martin, Unite Toxicodependance, Dept Psychiat, CH-1011 Lausanne, Switzerland
[4] Hop Cantonal Univ Geneva, Dept Psychiat, Montreux, Switzerland
[5] Unite Ambulatoire Specialisee, Montreux, Switzerland
[6] Univ Bern, Psychiat Dienste Bern, Bern, Switzerland
关键词
D O I
10.1016/j.clpt.2005.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Recent in vitro studies have suggested an important role of cytochrome P450 (CYP) 2B6 and CYP2C19 in methadone metabolism. We aimed to determine the influence of CYP2B6, CYP2C9, and CYP2C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. Methods. We included 209 patients in methadone maintenance treatment on the basis of their response to treatment and their daily methadone dose. Patients were genotyped for CYP2B6, CYP2C9, and CYP2C19. Steady-state trough and peak (R)-, (S)-, and (RS)-plasma levels and peak-to-trough plasma level ratios were measured. Results: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng (.) kg/mL (.) mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004). CYP2C9 and CYP2C19 genotypes do not influence methadone plasma levels. Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng (.) kg/mL (.) mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)]. Conclusion: Although CYP2B6 influences (S)-methadone plasma levels, given that only (R)-methadone contributes to the opioid effect of this drug, a major influence of CYP2B6 genotype on response to treatment is unlikely and has not been shown in this study. Lower plasma levels of methadone in nonresponders, suggesting a higher clearance, and higher peak-to-trough ratios, suggesting a shorter elimination half-life, are in agreement with the usual clinical measures taken for such patients, which are to increase methadone dosages and to split the daily dose into several intakes.
引用
收藏
页码:593 / 604
页数:12
相关论文
共 46 条
  • [21] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
    Iribarne, C
    Berthou, F
    Baird, S
    Dreano, Y
    Picart, D
    Bail, JP
    Beaune, P
    Menez, JF
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (02) : 365 - 373
  • [22] Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping
    Jacob, RM
    Johnstone, EC
    Neville, MJ
    Walton, RT
    [J]. CLINICAL CHEMISTRY, 2004, 50 (08) : 1372 - 1377
  • [23] Functional characterization of cytochrome P4502B6 allelic variants
    Jinno, H
    Tanaka-Kagawa, T
    Ohno, A
    Makino, Y
    Matsushima, E
    Hanioka, N
    Ando, M
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (04) : 398 - 403
  • [24] Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone
    Kharasch, ED
    Hoffer, C
    Whittington, D
    Sheffels, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) : 250 - 269
  • [25] Clinical consequences of cytochrome P4502C9 polymorphisms
    Kirchheiner, J
    Brockmöller, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 1 - 16
  • [26] Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
    Kirchheiner, J
    Klein, C
    Meineke, I
    Sasse, J
    Zanger, UM
    Mürdter, TE
    Roots, I
    Brockmöller, J
    [J]. PHARMACOGENETICS, 2003, 13 (10): : 619 - 626
  • [27] Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs
    Kreth, KP
    Kovar, KA
    Schwab, M
    Zanger, UM
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 59 (12) : 1563 - 1571
  • [28] Hepatic CYP2B6 expression:: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (Constitutive Androstane Receptor) expression
    Lamba, V
    Lamba, J
    Yasuda, K
    Strom, S
    Davila, J
    Hancock, ML
    Fackenthal, JD
    Rogan, PK
    Ring, B
    Wrighton, SA
    Schuetz, EG
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03) : 906 - 922
  • [29] Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
    Lang, T
    Klein, K
    Fischer, J
    Nüssler, AK
    Neuhaus, P
    Hofmann, U
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    [J]. PHARMACOGENETICS, 2001, 11 (05): : 399 - 415
  • [30] Leavitt SB, 2000, MT SINAI J MED, V67, P404